| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
7-Methylguanine primarily targets PARP1 (Poly(ADP-ribose) polymerase 1), an enzyme involved in DNA repair. It acts as a competitive inhibitor of PARP1 with a Ki of 61 μM, competing with the substrate NAD+. By inhibiting PARP1, the compound interferes with DNA repair mechanisms, leading to anticancer activity. As a natural nucleic acid metabolite, it serves as a probe for protein-DNA interactions. Its anticancer activity has been demonstrated against uterine sarcoma and colon adenocarcinoma.
|
|---|---|
| ln Vitro |
In vitro, 7-Methylguanine (0-200 μM) inhibits the activity of PARP1 enzyme in a dose-dependent manner. It is a competitive PARP-1 inhibitor with an inhibition constant (Ki) of 61 μM. 7-Methylguanine (0-450 μM) suppresses the catalytic activity of PARP-1, thereby preventing the dissociation of the PARP-1-DNA complex. After 24 hours of treatment with 7-Methylguanine (0.02-0.2 mg/mL), no DNA damage was observed in immortalized human renal epithelial cells (NKE-hTERT). The compound exhibits anticancer activity against uterine sarcoma and colon adenocarcinoma.
|
| ln Vivo |
In vivo, in CBA, BALB/c, and C57BL/6 mice, 7-Methylguanine (50 mg/kg, administered orally, three times per week for 4 weeks) did not cause adverse reactions or morphological changes, while it inhibited tumor growth in CBA mice with uterine sarcoma US-322. In BALB/c mice transplanted with Akatol tumors, 7-Methylguanine (50 mg/kg, administered via gavage, three times per week) effectively penetrated tumor tissues and suppressed the growth of colon adenocarcinoma. The compound is orally available.
|
| Enzyme Assay |
In vitro enzyme assays for 7-Methylguanine involve measuring PARP1 activity inhibition. PARP1 activity is assessed by measuring the incorporation of radiolabeled NAD+ into poly(ADP-ribose) polymers. The compound is added at varying concentrations (0-200 μM), and IC50 or Ki values are calculated from dose-response curves. Competitive inhibition is confirmed by varying substrate (NAD+) concentrations. DNA repair assays may be performed to assess functional consequences of PARP1 inhibition. Assays are performed in appropriate buffer systems with positive controls such as known PARP1 inhibitors (e.g., olaparib).
|
| Cell Assay |
In vitro cell-based assays for 7-Methylguanine are conducted in cancer cell lines including uterine sarcoma and colon adenocarcinoma cells. Cells are cultured in appropriate media at 37°C with 5% CO2 and treated with the compound at varying concentrations (0.02-0.2 mg/mL). Cell viability is assessed by MTT or CCK-8 assays. PARP1 activity is assessed by measuring PAR polymer levels by ELISA or Western blot. DNA damage is assessed by measuring γ-H2AX foci or comet assays. Apoptosis is evaluated by Annexin V/PI staining. Experiments are performed in triplicate with appropriate positive (e.g., olaparib) and negative (vehicle) controls.
|
| Animal Protocol |
In vivo animal studies for 7-Methylguanine are conducted in mouse models of uterine sarcoma and colon adenocarcinoma. CBA mice with uterine sarcoma US-322 or BALB/c mice transplanted with Akatol tumors are treated with 7-Methylguanine at 50 mg/kg, administered orally or via gavage, three times per week for 4 weeks. Tumor growth is monitored by caliper measurements. Body weight and clinical signs are monitored to assess toxicity. Tumor tissues are collected for histopathological and biomarker analysis. PARP1 inhibition in tumors is confirmed by measuring PAR polymer levels. Studies are conducted in accordance with institutional animal care guidelines.
|
| ADME/Pharmacokinetics |
7-Methylguanine (MW 165.15 g/mol, C6H7N5O) is a small molecule PARP1 inhibitor. It is soluble in 1M NaOH (80 mg/mL, 484.41 mM) and water (3.3 mg/mL, 19.98 mM, when pH is adjusted to 11 with 1M NaOH). The compound is stable as a powder at -20°C for up to 3 years and in solvent at -80°C for 1 year. It is orally available. Pharmacokinetic parameters such as half-life, bioavailability, and tissue distribution have been characterized in preclinical studies.
|
| Toxicity/Toxicokinetics |
7-Methylguanine is generally well-tolerated in preclinical studies. In CBA, BALB/c, and C57BL/6 mice, 7-Methylguanine (50 mg/kg, administered orally, three times per week for 4 weeks) did not cause adverse reactions or morphological changes. The compound is a natural nucleic acid metabolite with a favorable safety profile. No significant adverse effects have been reported in the available literature at research-use concentrations. The compound is intended for research use only. Standard safety precautions should be followed when handling. Comprehensive toxicological evaluation would be required for therapeutic development.
|
| References | |
| Additional Infomation |
2-Amino-7-methyl-7H-purin-6-ol is a 7-methylguanine, formed by substituting an amino group at the 2-position, a methyl group at the 7-position, and a hydroxyl group at the 6-position of 7H-purine. It is a tautomer of 2-amino-7-methyl-1,7-dihydro-6H-purin-6-one and 2-imino-7-methyl-1,2,3,7-tetrahydro-6H-purin-6-one. 7-Methylguanine is a metabolite found or produced in Saccharomyces cerevisiae.
7-Methylguanine is an orally available PARP1 inhibitor (Ki = 61 μM) that competes with NAD+ and exhibits anticancer activity. It is a natural nucleic acid metabolite used as a probe for protein-DNA interactions. The compound has anticancer activity against uterine sarcoma and colon adenocarcinoma. In vivo, it inhibits tumor growth in mouse models without causing adverse reactions. Its molecular formula is C6H7N5O with a molecular weight of 165.15 g/mol. All applications are limited to non-human research use. |
| Molecular Formula |
C6H7N5O
|
|---|---|
| Molecular Weight |
165.1527
|
| Exact Mass |
165.065
|
| CAS # |
578-76-7
|
| Related CAS # |
7-Methylguanine-d3;17829-03-7
|
| PubChem CID |
135398679
|
| Appearance |
White to light yellow solid powder
|
| Density |
1.8±0.1 g/cm3
|
| Boiling Point |
481.4±37.0 °C at 760 mmHg
|
| Melting Point |
370°C
|
| Flash Point |
244.9±26.5 °C
|
| Vapour Pressure |
0.0±1.3 mmHg at 25°C
|
| Index of Refraction |
1.865
|
| LogP |
-2.08
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
12
|
| Complexity |
250
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
FZWGECJQACGGTI-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C6H7N5O/c1-11-2-8-4-3(11)5(12)10-6(7)9-4/h2H,1H3,(H3,7,9,10,12)
|
| Chemical Name |
2-amino-7-methyl-1H-purin-6-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~302.76 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (15.14 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.0551 mL | 30.2755 mL | 60.5510 mL | |
| 5 mM | 1.2110 mL | 6.0551 mL | 12.1102 mL | |
| 10 mM | 0.6055 mL | 3.0276 mL | 6.0551 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
